Trialling remote methods of improving patient lives and adapting to systemic autoimmune rheumatic diseases

The ADAPT randomised controlled trial: Adapting, Disease self-management and Acknowledgement by Psychosocial Targeted interventions for rheumatology patients

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN72406488

Enrollment

920

Registered

2023-03-29

Start date

2023-04-18

Completion date

Unknown

Last updated

2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Systemic autoimmune rheumatic diseases (SARDs), Systemic lupus erythematosus (SLE) (lupus) Skin and Connective Tissue Diseases

Interventions

Participants will be allocated randomly (by block randomisation to ensure equal numbers per group) into one of four groups: 1. Control - no additional intervention 2. Text messaging support - to rece

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Aged 18 years or over 2. Resident in the UK or Ireland 3.1. Phase 1: Have SLE (lupus) as a diagnosis on clinic letters 3.2. Phase 2: Have any Systemic autoimmune rheumatic diseases (SARD) as a diagnosis on clinic letters

Exclusion criteria

Exclusion criteria: 1. Aged under 18 years 2. Not resident in the UK or Ireland. 3. Not having SLE (lupus) for phase 1 or any systemic rheumatic disease for phase 2.

Design outcomes

Primary

Measure	Time frame
Primary outcomes will be measured at Baseline and Follow-up 2 (6 months post baseline). Phase 1 will include testing multiple outcome measures for acceptability for Phase 2. Primary outcome measures for phase 1 are: 1. Loneliness measured using the UCLA 6 item loneliness scale (RULS-6) 2. Resilience using the Connor Davidson resilience scale Phase 2: Primary outcome to be selected from Phase 1 trial measures (listed below in secondary outcome measures) and pre-published prior to recruitment for phase 2.	—

Measure

Time frame

Primary outcomes will be measured at Baseline and Follow-up 2 (6 months post baseline). Phase 1 will include testing multiple outcome measures for acceptability for Phase 2. Primary outcome measures for phase 1 are: 1. Loneliness measured using the UCLA 6 item loneliness scale (RULS-6) 2. Resilience using the Connor Davidson resilience scale Phase 2: Primary outcome to be selected from Phase 1 trial measures (listed below in secondary outcome measures) and pre-published prior to recruitment for phase 2.

—

Secondary

Measure	Time frame
All measures at baseline, Follow-up 1 (Baseline+12 weeks) and Follow-up 2 (Baseline +6 months) 1. Loneliness measured using the UCLA 6 item loneliness scale (RULS-6) 2. Resilience using the Connor Davidson resilience scale 3. Anxiety measured using the GAD-7 scale 4. Depression measured using PHQ-8 5. Adapting to a chronic disease measured using our own new ADAPT instrument 6. Fatigue measured using the FACIT-F 7. Quality of life measured using EQ-5D-5L	—

Measure

Time frame

All measures at baseline, Follow-up 1 (Baseline+12 weeks) and Follow-up 2 (Baseline +6 months) 1. Loneliness measured using the UCLA 6 item loneliness scale (RULS-6) 2. Resilience using the Connor Davidson resilience scale 3. Anxiety measured using the GAD-7 scale 4. Depression measured using PHQ-8 5. Adapting to a chronic disease measured using our own new ADAPT instrument 6. Fatigue measured using the FACIT-F 7. Quality of life measured using EQ-5D-5L

—

Countries

England, Ireland, United Kingdom

Contacts

Public ContactMelanie Sloan

mas229@medschl.cam.ac.uk+44 7975799052

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026